Expression of KIT (CD117) in renal cell carcinoma and renal oncocytoma

Oncology

Volumn 68, Issue 2-3, 2005, Pages 269-275

  Krüger, Stefan ^a   Sotlar, Karl ^b   Kausch, Ingo ^a   Horny, Hans Peter ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Immunohistochemistry; KIT; Renal cell carcinoma

Indexed keywords

STEM CELL FACTOR RECEPTOR; TUMOR MARKER;

ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; CELL MEMBRANE; CORRELATION ANALYSIS; CYTOPLASM; EXON; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; KIDNEY ONCOCYTOMA; MALE; ONCOCYTOMA; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TUMOR CELL; CANCER STAGING; CHEMISTRY; GENE EXPRESSION REGULATION; KIDNEY TUMOR; MIDDLE AGED; PATHOLOGY;

ADENOMA, OXYPHILIC; AGED; CARCINOMA, RENAL CELL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROTO-ONCOGENE PROTEINS C-KIT; TUMOR MARKERS, BIOLOGICAL;

EID: 23844442288     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000086783     Document Type: Article

References (27)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ: Cancer statistics, 2003. CA Cancer J Clin 2003;53:5-26.
2. Ljungberg B, Alamdari FI, Stenling R, Roos G: Prognostic significance of the Heidelberg classification of renal cell carcinoma. Eur Urol 1999;36:565-569.
3. Yarden Y, Kuang WJ, Yang FT, Coussens L, Munemitsu S, Dull TJ, Chen E, Schlessinger J, Francke U, Ullrich A: Human proto-oncogene c-kit: A new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J 1987;6:3341-3351.
4. Qiu FH, Ray P, Brown K, Barker PE, Jhanwar S, Ruddle FH, Besmer P: Primary structure of c-kit: Relationship with the CSF-1/PDGF receptor kinase family - Oncogenic activation of v-kit involves deletion of extracellular domain and C terminus. EMBO J 1988;7:1003-1011.
5. Lev S, Yarden Y, Givol D: Dimerization and activation of the kit receptor by monovalent and bivalent binding of the stem cell factor. J Biol Chem 1992;267:15970-15977.
6. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, Muhammad-Tunio G, Matsuzawa Y, Kanakura Y, Shinomura Y, Kitamura Y: Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998;279:577-580.
7. Kitayama H, Kanakura Y, Kuritsu T, Tsujimura T, Oritani K, Ikeda H, Sugahara H, Mitsui H, Kanayama Y, Kitamura Y, Matsuzawa Y: Constitutively activating mutations of c-kit receptor tyrosine kinase confer factor-independent growth and tumorigenicity of factor-dependent hematopoietic cell lines. Blood 1995;85:790-798.
8. Longley BJ, Tyrrell L, Lu SZ, Ma YS, Langley K, Ding TG, Duffy T, Jacobs P, Tang LH, Modlin I: Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: Establishment of clonality in a human mast cell neoplasm. Nat Genet 1996;12:312-314.
9. Sotlar K, Marafioti T, Griesser H, Theil J, Aepinus C, Jaussi R, Stein H, Valent P, Horny HP: Detection of c-kit mutation Asp 816 to Val in microdissected bone marrow infiltrates in a case of systemic mastocytosis associated with chronic myelomonocytic leukaemia. Mol Pathol 2000;53:188-193.
10. Merchant MS, Woo CW, Mackall CL, Thiele CJ: Potential use of imatinib in Ewing's sarcoma: Evidence for in vitro and in vivo activity. J Natl Cancer Inst 2002;94:1673-1679.
11. Tian Q, Frierson HF Jr, Krystal GW, Moskaluk CA: Activating c-kit gene mutations in human germ cell tumors. Am J Pathol 1999;154:1643-1647.
12. Ma Y, Zeng S, Metcalfe DD, Akin C, Dimitrijevic S, Butterfield JH, McMahon G, Longley BJ: The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood 2002;99:1741-1744.
13. Schmandt RE, Broaddus R, Lu KH, Shvartsman H, Thornton A, Malpica A, Sun C, Bodurka DC, Gershenson DM: Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-β in ovarian serous carcinoma and normal ovarian surface epithelium. Cancer 2003;98:758-764.
14. Jeng YM, Lin CY, Hsu HC: Expression of the c-kit protein is associated with certain subtypes of salivary gland carcinoma. Cancer Lett 2000;154:107-111.
15. Pache M, Glatz K, Bösch D, Dirnhofer S, Mirlacher M, Simon R, Schraml P, Rufle A, Flammer J, Sauter G, Meyer P: Sequence analysis and high-throughput immunohistochemical profiling of KIT (CD117) expression in uveal melanoma using tissue microarrays. Virchows Arch 2003;443:741-744.
16. Yamazaki K, Sakamoto M, Ohta T, Kanai Y, Ohki M, Hirohashi S: Overexpression of KIT in chromophobe renal cell carcinoma. Oncogene 2003;22:847-852.
17. Sotlar K, Escribano L, Landt O, Möhrle S, Herrero S, Torrelo A, Lass U, Horny HP, Bültmann B: One-step detection of c-kit point mutations using peptide nucleic acid-mediated polymerase chain reaction clamping and hybridization probes. Am J Pathol 2003;162:737-746.
18. Mathers ME, Pollock AM, Marsh C, O'Donnell M: Cytokeratin 7: A useful adjunct in the diagnosis of chromophobe renal cell carcinoma. Histopathology 2002;40:563-567.
19. Thoenes W, Störkel S, Rumpelt HJ: Human chromophobe cell renal carcinoma. Virchows Arch B Cell Pathol Incl Mol Patho 1985;48:207-217.
20. Störkel S, Martignoni G, van den Berg E: Chromophobe renal cell carcinoma; in Eble JN, Sauter G, Epstein JI, Sesterhenn IA (eds): Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon, IARC Press, 2004, pp 30-32.
21. Mostofi FK, Davis CJ (eds): Histological Typing of Kidney Tumours, ed 2, revised. Berlin, Springer, 1998.
22. Wittekind C, Meyer HJ, Bootz F: TNM-Klassifikation malignes Tumoren, ed 6. Berlin, Springer, 2003.
23. Furitsu T, Tsujimura T, Tono T, Ikeda H, Kitayama H, Koshimizu U, Sugahara H, Butterfield JH, Ashman LK, Kanayama Y, et al.: Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukaemia cell line causing ligand-independent activation of c-kit product. J Clin Invest 1993;92:1736-1744.
24. Presti JC Jr, Rao PH, Chen Q, Reuter VE, Li FP, Fair WR, Jhanwar SC: Histopathological, cytogenetic, and molecular characterization of renal cortical tumors. Cancer Res 1991;51:1544-1552.
25. Kovacs G, Akhtar M, Beckwith BJ, Bugert P, Cooper CS, Delahunt B, Eble JN, Fleming S, Ljungberg B, Medeiros LJ, Moch H, Reuter VE, Ritz E, Roos G, Schmidt D, Srigley JR, Störkel S, van den Berg E, Zbar B: The Heidelberg classification of renal cell tumours. J Pathol 1997;183:131-133.
26. Petit A, Castillo M, Santos M, Mellado B, Alcover JB, Mallofre C: KIT expression in chromophobe renal cell carcinoma: Comparative imunohistochemical analysis of KIT expression in different renal cell neoplasms. Am J Surg Pathol 2004;28:676-678.
27. Frost MJ, Ferrao PT, Hughes TP, Ashman LK: Juxtamembrane mutant V560GKit is more sensitive to imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant. Mol Cancer Ther 2002;1:1115-1124.